Northeast Financial Consultants’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $213K | Buy |
+1,876
| New | +$213K | 0.01% | 282 |
|
|
2025
Q1 | – | Sell |
-1,876
| Closed | -$201K | – | 287 |
|
|
2024
Q4 | $201K | Buy |
+1,876
| New | +$201K | 0.01% | 278 |
|
|
2022
Q3 | – | Sell |
-4,416
| Closed | -$245K | – | 349 |
|
|
2022
Q2 | $245K | Hold |
4,416
| – | – | 0.02% | 282 |
|
|
2022
Q1 | $309K | Buy |
4,416
+1,409
| +47% | +$98.6K | 0.02% | 296 |
|
|
2021
Q4 | $290K | Hold |
3,007
| – | – | 0.02% | 286 |
|
|
2021
Q3 | $261K | Hold |
3,007
| – | – | 0.02% | 297 |
|
|
2021
Q2 | $246K | Buy |
+3,007
| New | +$246K | 0.02% | 313 |
|
|
2020
Q3 | – | Sell |
-3,070
| Closed | -$214K | – | 307 |
|
|
2020
Q2 | $214K | Buy |
+3,070
| New | +$214K | 0.02% | 259 |
|
|
2020
Q1 | – | Sell |
-3,070
| Closed | -$200K | – | 296 |
|
|
2019
Q4 | $200K | Buy |
+3,070
| New | +$200K | 0.02% | 292 |
|
|
2019
Q3 | – | Sell |
-3,070
| Closed | -$219K | – | 327 |
|
|
2019
Q2 | $219K | Hold |
3,070
| – | – | 0.02% | 295 |
|
|
2019
Q1 | $241K | Buy |
+3,070
| New | +$241K | 0.03% | 268 |
|